Click on image to view larger version.

Figure 1 In-hospital mortality rates of SHOCK Trial Registry patients with predominant left ventricular failure. Patients receiving thrombolytic therapy had significantly lower mortality than those not receiving thrombolytic therapy in the overall cohort (p = 0.005), and this benefit was independent of IABP use (interaction p = 0.126). There was a significant difference in in-hospital mortality among the 4 subsets of patients treated with thrombolysis with IABP, thrombolysis without IABP, IABP alone or neither. Treatments were selected by local physicians. In each of these subsets, patients who underwent revascularization had lower mortality than those who were not revascularized (p < 0.0002).